EASl ILC 2021
The Digital ILC 2021
23-26 June, 2021
To help you get as much value from Digital ILC as possible, we have identified 16 presentations and posters we find most interesting. Our daily podcasts will summarize these and discuss what they suggest for the future of NASH/NAFLD therapies.
Thursday June 23, 2021
Our Surfers Discussed The Following Papers and Sessions on Day 2
Livia Alimena — EASL-CDC symposium COVID-19 and the liver — vaccination, variants and continuity of care
Naim Alkhouri — OS-1611 AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial endpoints
Michelle Long — OS-1780 Incidence rates of select outcomes among patients with NASH and evidence of fibrosis or cirrhosis
Jörn Schattenberg — OS-293 Life expectancy and risk of cardiovascular disease in non-alcoholic fatty liver disease: a population-based cohort study
Roger Green — OS-612 Lean NAFLD from the General French Population have more Severe Liver Disease and Poorer Clinical Outcomes (NASH-CO-study)
Surfing The NASH Tsunami Podcast Day 2
Friday June 25, 2021
Our Surfers Will Discuss The Following Papers and Sessions on Day 3
Louise Campbell MSc AP — Symposium: Improving outcomes in liver disease: the role of primary care physicians
Manal Abdelmalek — PO-230: Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial
Ken Cusi — OS-1044: Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages
Ian Rowe — PO-2377: Canagliflozin and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus (CaNAFLD) – A Secondary Analysis of Two Randomized Controlled Trials
Roger Green — Treatment of NAFLD with intermittent calorie restriction, low-carb high-fat diet or standard dietary advice – a randomized controlled trial.
Saturday, June 26, 2021
Our Surfers Discussed The Following Papers and Sessions on Day 4
Donna Cryer — OS-243 : Comparative diagnostic accuracy of blood-based biomarkers for staging fibrosis in NAFLD: phase 1 results of the LITMUS project
Mazen Noureddin — OS-555: Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with non-alcoholic fatty liver disease
Michael Charlton — LBP-2907: Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial
Vlad Ratziu — LBO-2800: Efruxifermin (EFX) improved markers of fibrosis, liver injury and metabolism in F4 NASH patients with compensated cirrhosis
Roger Green — OS-2854: Elderly with advanced liver fibrosis had lower response to Pfizer’s SARS-CoV-2 vaccine response
Surfing The NASH Tsunami Podcast Day 4
Available In Your Favorite Podcast App:
